Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Mark-Lanasa"

2 News Found

China NMPA approves Tislelizumab for metastatic nasopharyngeal cancer
Drug Approval | June 12, 2022

China NMPA approves Tislelizumab for metastatic nasopharyngeal cancer

Tislelizumab is now approved in nine indications in China


China approves BeiGene’s tislelizumab
Drug Approval | March 12, 2022

China approves BeiGene’s tislelizumab

Tislelizumab is now approved for seven indications in China